资讯

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...
There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...
Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System ...
Overview of Companion Diagnostics MarketThe Companion Diagnostics Market is evolving rapidly, driven by the growing demand ...
CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...
The CHMP’s recommendation for ZURZUVAE will now be reviewed by the EC for marketing authorization in the European Union with a final decision expected in the third quarter of 2025. The U.S. FDA ...
Empower Pharmacy, a Houston-based compounding pharmacy, has been sanctioned by the FDA and other states in the past decade.
The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.
GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...
Since Dr. Vinay Prasad’s appointment as a key political voice within FDA, the tone of U.S. biotech policy has shifted from ...
Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...
Stoned AI delivers hallucinations and headaches The Trump administration is flogging artificial intelligence as the silver ...